Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Head and Neck Pathology
Published in: Head and Neck Pathology 1/2022

Open Access 01-03-2022 | Otosclerosis | Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors

Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumours: Tumours of the Ear

Author: Ann Sandison

Published in: Head and Neck Pathology | Issue 1/2022

Login to get access

Abstract

In the recently published 5th Edition of the World Health Organisation Classification of Head and Neck Tumours, there are relatively few changes to report in terms of nomenclature in lesions of ear and temporal bone and fewer developments in molecular pathogenesis in comparison to other sites, particularly in sinonasal tract. Ear and temporal bone tumours are rare and biopsy material is limited. As a result, resources in the literature are scarce with few large series, no controlled clinical trials and the approaches to staging and management are not standardised. New entities are difficult to characterise. The number of entries has, however, increased for tumours of the ear and temporal bone (thirteen) compared to the 4th Edition (eleven). Some lesions previously included in the 4th Edition considered to have no site-specific features have been excluded to be discussed elsewhere and other benign lesions that are specific to this site have been included. The tumours and tumour-like entities of ear and temporal bone are discussed here mindful that the chapter in the 5th edition better correlates disease processes with clinical information and imaging and as far as possible standardises nomenclature.
Literature
1.
Gupta R, et al. Data set for the reporting of ear and temporal bone tumors: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Arch Pathol Lab Med. 2019;143(5):593–602.PubMedCrossRef
2.
Salah H, Urso B, Khachemoune A. Review of the etiopathogenesis and management options of chondrodermatitis nodularis chronica helicis. Cureus. 2018;10(3):e2367.PubMedPubMedCentral
3.
Collins RJ, Yu HC. Pleomorphic adenoma of the external auditory canal. An immunohistochemical and ultrastructural study. Cancer. 1989;64(4):870–5.PubMedCrossRef
4.
Thompson LD, Nelson BL, Barnes EL. Ceruminous adenomas: a clinicopathologic study of 41 cases with a review of the literature. Am J Surg Pathol. 2004;28(3):308–18.PubMedCrossRef
5.
Lott Limbach AA, et al. Middle ear adenomas stain for two cell populations and lack myoepithelial cell differentiation. Head Neck Pathol. 2012;6(3):345–53.PubMedPubMedCentralCrossRef
6.
7.
Andreasen S, et al. Genetic rearrangements, hotspot mutations, and microRNA expression in the progression of metastatic adenoid cystic carcinoma of the salivary gland. Oncotarget. 2018;9(28):19675–87.PubMedPubMedCentralCrossRef
8.
West RB, et al. MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. Am J Surg Pathol. 2011;35(1):92–9.PubMedPubMedCentralCrossRef
9.
Brill LB 2nd, et al. Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms. Mod Pathol. 2011;24(9):1169–76.PubMedCrossRef
10.
Shah AA, Oliai BR, Bishop JA. Consistent LEF-1 and MYB immunohistochemical expression in human papillomavirus-related multiphenotypic sinonasal carcinoma: a potential diagnostic pitfall. Head Neck Pathol. 2019;13(2):220–4.PubMedCrossRef
11.
Park S, et al. Clinicopathologic implications of Myb and beta-catenin expression in adenoid cystic carcinoma. J Otolaryngol Head Neck Surg. 2020;49(1):48.PubMedPubMedCentralCrossRef
12.
13.
14.
15.
Declau F, et al. Prevalence of otosclerosis in an unselected series of temporal bones. Otol Neurotol. 2001;22(5):596–602.PubMedCrossRef
16.
Karosi T, Szekanecz Z, Sziklai I. Otosclerosis: an autoimmune disease? Autoimmun Rev. 2009;9(2):95–101.PubMedCrossRef
17.
18.
Gordon MA. The genetics of otosclerosis: a review. Am J Otol. 1989;10(6):426–38.PubMed
19.
Larsson A. Otosclerosis. A genetic and clinical study. Acta Otolaryngol Suppl. 1960;154:1–86.PubMed
20.
Mavromara-Nazos P, Roizman B. Activation of herpes simplex virus 1 gamma 2 genes by viral DNA replication. Virology. 1987;161(2):593–8.PubMedCrossRef
21.
Vincent R, et al. Surgical findings and long-term hearing results in 3,050 stapedotomies for primary otosclerosis: a prospective study with the otology-neurotology database. Otol Neurotol. 2006;27(8 Suppl 2):S25-47.PubMedCrossRef
22.
Rudic M, et al. The pathophysiology of otosclerosis: review of current research. Hear Res. 2015;330(Pt A):51–6.PubMedCrossRef
23.
Michaels L, Soucek S. Atypical mature bone in the otosclerotic otic capsule as the differentiated zone of an invasive osseous neoplasm. Acta Otolaryngol. 2014;134(2):118–23.PubMedCrossRef
24.
Luers JC, Huttenbrink KB. Surgical anatomy and pathology of the middle ear. J Anat. 2016;228(2):338–53.PubMedCrossRef
25.
Persaud R, et al. Epidermoid formation: the potential precursor of congenital cholesteatomas. Am J Otolaryngol. 2006;27(1):71–2 (author reply 72).PubMedCrossRef
26.
Wenig BM. Schneiderian-type mucosal papillomas of the middle ear and mastoid. Ann Otol Rhinol Laryngol. 1996;105(3):226–33.PubMedCrossRef
27.
28.
Blandamura S, et al. Temporal bone and sinonasal inverted papilloma: the same pathological entity? Arch Otolaryngol Head Neck Surg. 2003;129(5):553–6.PubMedCrossRef
29.
Marioni G, et al. Detection of human papillomavirus in temporal bone inverted papilloma by polymerase chain reaction. Acta Otolaryngol. 2003;123(3):367–71.PubMedCrossRef
30.
Carlson ML, et al. Inverting papilloma of the temporal bone: report of four new cases and systematic review of the literature. Laryngoscope. 2015;125(11):2576–83.PubMedCrossRef
31.
Bayindir E, et al. a case of inverted papilloma originating from the middle ear and review of the literature. Case Rep Otolaryngol. 2019;2019:3041570.PubMedPubMedCentral
32.
Thompson LDR. Middle ear and temporal bone papilloma: a clinicopathologic study and comprehensive literature review of 57 cases. Head Neck Pathol. 2021;15(4):1212–20.PubMedCrossRef
33.
Altavilla G, et al. Expression of p53, p16INK4A, pRb, p21WAF1/CIP1, p27KIP1, cyclin D1, Ki-67 and HPV DNA in sinonasal endophytic Schneiderian (inverted) papilloma. Acta Otolaryngol. 2009;129(11):1242–9.PubMedCrossRef
34.
Martignoni G, et al. Molecular pathology of lymphangioleiomyomatosis and other perivascular epithelioid cell tumors. Arch Pathol Lab Med. 2010;134(1):33–40.PubMedCrossRef
35.
Stoddard DG Jr, et al. Transcriptional activity of HPV in inverted papilloma demonstrated by in situ hybridization for E6/E7 mRNA. Otolaryngol Head Neck Surg. 2015;152(4):752–8.PubMedCrossRef
36.
Cheung FM, et al. Schneiderian papillomas and carcinomas: a retrospective study with special reference to p53 and p16 tumor suppressor gene expression and association with HPV. Ear Nose Throat J. 2010;89(10):E5–12.PubMedCrossRef
37.
Udager AM, et al. Human papillomavirus (HPV) and somatic EGFR mutations are essential, mutually exclusive oncogenic mechanisms for inverted sinonasal papillomas and associated sinonasal squamous cell carcinomas. Ann Oncol. 2018;29(2):466–71.PubMedCrossRef
38.
Udager AM, et al. Activating KRAS mutations are characteristic of oncocytic sinonasal papilloma and associated sinonasal squamous cell carcinoma. J Pathol. 2016;239(4):394–8.PubMedCrossRef
39.
Taverna C, et al. Papillary-cystic neoplasms of the middle ear are distinct from endolymphatic sac tumours. Histopathology. 2021;79(3):306–14.PubMedCrossRef
40.
Stemmer-Rachamimov AO, et al. Universal absence of merlin, but not other ERM family members, in schwannomas. Am J Pathol. 1997;151(6):1649–54.PubMedPubMedCentral
41.
Bachir S, et al. Neurofibromatosis type 2 (NF2) and the implications for vestibular schwannoma and meningioma pathogenesis. Int J Mol Sci. 2021;22(2):690.PubMedCentralCrossRef
42.
Jacoby LB, et al. Frequency and distribution of NF2 mutations in schwannomas. Genes Chromosom Cancer. 1996;17(1):45–55.PubMedCrossRef
43.
Lassaletta L, et al. NF2 genetic alterations in sporadic vestibular schwannomas: clinical implications. Otol Neurotol. 2013;34(7):1355–61.PubMedCrossRef
44.
Oh JE, et al. Alterations in the NF2/LATS1/LATS2/YAP pathway in schwannomas. J Neuropathol Exp Neurol. 2015;74(10):952–9.PubMedCrossRef
45.
Havik AL, et al. Genetic landscape of sporadic vestibular schwannoma. J Neurosurg. 2018;128(3):911–22.PubMedCrossRef
46.
Karamchandani JR, et al. Sox10 and S100 in the diagnosis of soft-tissue neoplasms. Appl Immunohistochem Mol Morphol. 2012;20(5):445–50.PubMedCrossRef
47.
Miettinen M, et al. Sox10—a marker for not only Schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: a systematic analysis of 5134 tumors. Am J Surg Pathol. 2015;39(6):826–35.PubMedPubMedCentralCrossRef
48.
Xu B, Chetty R, Perez-Ordonez B. Neuroendocrine neoplasms of the head and neck: some suggestions for the new WHO classification of head and neck tumors. Head Neck Pathol. 2014;8(1):24–32.PubMedPubMedCentralCrossRef
49.
Asa SL, et al. Middle ear “Adenoma”: a neuroendocrine tumor with predominant L cell differentiation. Endocr Pathol. 2021;32(4):433–41.PubMedCrossRef
50.
Torske KR, Thompson LD. Adenoma versus carcinoid tumor of the middle ear: a study of 48 cases and review of the literature. Mod Pathol. 2002;15(5):543–55.PubMedCrossRef
51.
Agaimy A, et al. “Neuroendocrine” middle ear adenomas: consistent expression of the transcription factor ISL1 further supports their neuroendocrine derivation. Histopathology. 2015;66(2):182–91.PubMedCrossRef
52.
Rooper LM, Bishop JA, Westra WH. INSM1 is a sensitive and specific marker of neuroendocrine differentiation in head and neck tumors. Am J Surg Pathol. 2018;42(5):665–71.PubMedCrossRef
53.
Rindi G, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770–86.PubMedPubMedCentralCrossRef
54.
Todorovic E, et al. Middle ear and temporal bone nonkeratinizing squamous cell carcinomas with DEK-AFF2 fusion: an emerging entity. Am J Surg Pathol. 2020;44(9):1244–50.PubMedCrossRef
55.
56.
Tysome JR, et al. Aggressive papillary tumor of the middle ear: a true entity or an endolymphatic sac neoplasm? Ear Nose Throat J. 2008;87(7):378–93.PubMedCrossRef
57.
Kawabata S, et al. Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone. Oncotarget. 2015;6(13):11357–68.PubMedPubMedCentralCrossRef
58.
Thompson LDR, et al. CAIX and pax-8 commonly immunoreactive in endolymphatic sac tumors: a clinicopathologic study of 26 cases with differential considerations for metastatic renal cell carcinoma in von Hippel-Lindau patients. Head Neck Pathol. 2019;13(3):355–63.PubMedCrossRef
59.
Kohan D, et al. Uncommon lesions presenting as tumors of the internal auditory canal and cerebellopontine angle. Am J Otol. 1997;18(3):386–92.PubMed
60.
Lammers G, Jamieson JC. The role of a cathepsin D-like activity in the release of Gal beta 1-4GlcNAc alpha 2-6-sialyltransferase from rat liver Golgi membranes during the acute-phase response. Biochem J. 1988;256(2):623–31.PubMedPubMedCentralCrossRef
61.
Codreanu CM, et al. Endolymphatic sac tumors in von Hippel-Lindau disease: report of three cases. Otol Neurotol. 2010;31(4):660–4.PubMedCrossRef
62.
Codreanu C, Trana Ba Huy P. Isolate vertigo crisis revealing an endolymphatic sac tumor. Rom J Morphol Embryol. 2010;51(2):387–9.PubMed
63.
Timmer FC, et al. Endolymphatic sac tumors: clinical outcome and management in a series of 9 cases. Otol Neurotol. 2011;32(4):680–5.PubMedCrossRef
64.
65.
Bausch B, et al. Characterization of endolymphatic sac tumors and von Hippel-Lindau disease in the International Endolymphatic Sac Tumor Registry. Head Neck. 2016;38(Suppl 1):E673–9.PubMedCrossRef
66.
Megerian CA, et al. Endolymphatic sac tumors: histopathologic confirmation, clinical characterization, and implication in von Hippel-Lindau disease. Laryngoscope. 1995;105(8 Pt 1):801–8.PubMedCrossRef
67.
El-Naggar AK, et al. Tumors of the middle ear and endolymphatic sac. Pathol Annu. 1994;29(Pt 2):199–231.PubMed
68.
Megerian CA, et al. Differential expression of transthyretin in papillary tumors of the endolymphatic sac and choroid plexus. Laryngoscope. 1997;107(2):216–21.PubMedCrossRef
69.
Horiguchi H, et al. Endolymphatic sac tumor associated with a von Hippel-Lindau disease patient: an immunohistochemical study. Mod Pathol. 2001;14(7):727–32.PubMedCrossRef
70.
Jensen RL, et al. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression. J Neurosurg. 2004;100(3):488–97.PubMedCrossRef
71.
Bisceglia M, D’Angelo VA, Wenig BM. Endolymphatic sac papillary tumor (Heffner tumor). Adv Anat Pathol. 2006;13(3):131–8.PubMedCrossRef
72.
Skalova A, et al. Endolymphatic sac tumor (aggressive papillary tumor of middle ear and temporal bone): report of two cases with analysis of the VHL gene. Pathol Res Pract. 2008;204(8):599–606.PubMedCrossRef
73.
74.
Sykopetrites V, et al. The endolymphatic sac tumor: challenges in the eradication of a localized disease. Eur Arch Otorhinolaryngol. 2021;278(7):2297–304.PubMedCrossRef
Metadata
Title
Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumours: Tumours of the Ear
Author
Ann Sandison
Publication date
01-03-2022
Publisher
Springer US
Published in
Head and Neck Pathology / Issue 1/2022
Electronic ISSN: 1936-0568
DOI
https://doi.org/10.1007/s12105-022-01450-9

Other articles of this Issue 1/2022

Head and Neck Pathology 1/2022 Go to the issue

Original Paper

Peripheral Versus Intraparenchymal Papillary Thyroid Microcarcinoma: Different Morphologies and PD-L1 Expression

Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors

Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Salivary Glands

UPDATE FROM THE 5TH EDITION OF THE WORLD HEALTH ORGANIZATION CLASSIFICATION OF HEAD AND NECK TUMORS

Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Tumours of the Oral Cavity and Mobile Tongue

Proceeding of the North American Society of Head and Neck Pathology Companion Meeting, March 20, 2022, Los Angeles, CA

Proceedings of the North American Society of Head and Neck Pathology, Los Angeles, CA, March 20, 2022. Emerging Bone and Soft Tissue Neoplasms in the Head and Neck Region

Proceeding of the North American Society of Head and Neck Pathology Companion Meeting, March 20, 2022, Los Angeles, CA

Proceedings of the North American Society of Head and Neck Pathology, Los Angeles, CA, March 20, 2022: SWI/SNF-deficient Sinonasal Neoplasms: An Overview

Original Paper

Oral Lymphoepithelial Cyst: A Collaborative Clinicopathologic Study of 132 Cases from Brazil